story of the week
Adjuvant Pembrolizumab vs Placebo in Resected Stage III Melanoma: Distant Metastasis–Free Results
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
The Lancet Oncology
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Adjuvant Pembrolizumab Versus Placebo in Resected Stage III Melanoma (EORTC 1325-MG/KEYNOTE-054): Distant Metastasis-Free Survival Results From a Double-Blind, Randomised, Controlled, Phase 3 Trial
Lancet Oncol 2021 Apr 12;[EPub Ahead of Print], AMM Eggermont, CU Blank, M Mandalà, GV Long, VG Atkinson, S Dalle, AM Haydon, A Meshcheryakov, A Khattak, MS Carlino, S Sandhu, J Larkin, S Puig, PA Ascierto, P Rutkowski, D Schadendorf, R Koornstra, L Hernandez-Aya, AM Di Giacomo, AJM van den Eertwegh, JJ Grob, R Gutzmer, R Jamal, PC Lorigan, ACJ van Akkooi, C Krepler, N Ibrahim, S Marreaud, M Kicinski, S Suciu, C RobertFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.